MRNA Is Poised to Rise Beyond Infectious Diseases, if It’s Not Derailed by R&D Cuts
mRNA technology, once celebrated for COVID‑19 vaccines, now faces heightened political and regulatory scrutiny, including the cancellation of roughly $500 million in BARDA contracts. A new JAMA Network Open study shows NIH has invested $1.65 billion in 178 mRNA grants since 1997, with only 75 aimed at vaccines and the remainder covering cancer, neurological, cardiovascular and rare‑disease research. The analysis highlights over 2,300 publications and significant involvement of small biotech firms through SBIR and STTR programs. Ongoing anti‑mRNA sentiment could jeopardize decades of progress across these therapeutic areas.
Novo Nordisk Launches Subscription Program for Wegovy Drugs
Novo Nordisk introduced a subscription service for its obesity treatment Wegovy, allowing cash‑pay patients to lock in three‑month, six‑month or twelve‑month supplies. The model promises lower out‑of‑pocket costs compared with traditional pay‑per‑dose purchases. By bundling shots and oral pills, Novo...
UCB Brings First Therapy for Rare Disease TK2d to EU
UCB’s Kygevi, a combination of doxecitine and doxribtimine, received its first EU approval for treating thymidine kinase 2 deficiency (TK2d) under exceptional circumstances. The drug, aimed at patients whose disease began before age 12, cut mortality risk by 95% compared with...
PepGen’s Muscle Disease Program Posts Poor Mid-Stage Results as One Patient's Data Get Markedly Worse
PepGen reported that its Phase 2 trial of an oligonucleotide therapy for a rare genetic nerve‑muscle disorder failed to meet its primary efficacy endpoints. The data showed no statistically significant improvement in muscle strength across the cohort, and one participant experienced...
Biogen Buys Apellis for $5.6B, Adds SYFOVRE Sales‑linked CVR
1/Another mega M&A deal in the BioTech and Pharma sector with the acquisition of Apellis Pharmaceuticals - $APLS by Biogen $BIIB for $41 per share in cash at closing in a $5.6B deal. In addition, Apellis stockholders will also receive...
O-GlcNAcylation of UGDH: New Immunometabolic Insights
Researchers led by Wu, Lei and Wang have shown that O‑GlcNAcylation of the metabolic enzyme UGDH reshapes its activity, steering UDP‑glucuronic acid production and downstream glycan synthesis. This post‑translational modification links nutrient‑sensing pathways to immune cell adhesion, migration, and signaling,...
Eli Lilly to Buy Centessa for $6.3B to Get Sleep Disorder Drug
Eli Lilly announced a $6.3 billion acquisition of Centessa Pharmaceuticals, marking its largest deal in years. The purchase secures Centessa’s orexin‑based insomnia candidate and a pipeline of early‑stage neurological programs. Lilly is channeling cash generated by its GLP‑1 blockbuster drugs into the...
First Clinical Trial of tRNA Therapy Will Start Soon
Alltrna, a biotech startup focused on transfer RNA (tRNA) therapeutics, has secured regulatory clearance to launch its first human clinical trial. The trial will evaluate a novel tRNA‑based drug designed to correct protein synthesis errors that underlie a range of...
Enveda's First Clinical Readout Shows Strong Eczema Results
Enveda Biosciences released its first clinical readout for an investigational atopic dermatitis therapy, showing efficacy comparable to AbbVie's Dupixent. The Phase 1 trial met its primary endpoints, demonstrating significant skin clearance and a safety profile similar to existing biologics. The...
Women’s Hereditary Cancer Testing: From Specialist to Self-Refer
Direct‑to‑consumer genetic testing is reshaping how women assess hereditary cancer risk, allowing them to bypass the traditional NHS referral pathway that required GP and genetics team approval. Private providers such as Jeen Health now offer clinically validated panels via at‑home...
Semarion Raises $3.8M to Scale Cell Assay Technology
Semarion, a Cambridge spin‑out, secured $3.8 million (≈£2.9 million) in a Series A round led by Parkwalk to scale its SemaCyte cell‑based screening platform. The funding follows a $2.89 million seed round in 2022 and will be used to expand manufacturing, field support,...
Alterity Receives Positive FDA Feedback on ATH434 Phase 3 Program
Alterity Therapeutics received positive written feedback from the U.S. Food and Drug Administration after a Type C meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy. The agency endorsed the company’s clinical pharmacology and non‑clinical development strategy and...
New Studies Boost Depression Recovery: Functional Framing and Extended Ketamine Effects
Two peer‑reviewed studies released this week reshape how depression is treated. Psychologists found that describing depression as a functional signal, not a brain defect, improves patients' expectations and reduces perceived chronicity. Meanwhile, Japanese neuroscientists identified the enzyme NOX‑1 as an...
Study Finds Daily Multivitamin Slows Epigenetic Aging Markers in Seniors
A randomized trial of 958 adults aged around 70 found that two years of daily multivitamin–multimineral supplementation reduced the yearly rise of two epigenetic clocks by 2.6 and 1.4 months respectively. The modest effect, published in Nature Medicine, fuels debate...
A Gut Microbiome Response to Low Protein Intake Drives Beneficial Browning of Fat Tissue
Researchers have shown that low‑protein diets (LPDs) stimulate the conversion of white adipose tissue into thermogenic beige fat, mirroring effects seen with cold exposure or β‑adrenergic activation. The browning response depends on specific gut microbes; germ‑free mice fail to brown,...
RenovoRx Posts $11.2M FY25 Loss, Sets Mid‑2026 Target for Phase III TIGeR‑PaC Enrollment
RenovoRx announced a widened FY25 net loss of $11.2 million, despite its first full year of revenue from the FDA‑cleared RenovoCath device. The company also outlined a timeline to complete enrollment for its Phase III TIGeR‑PaC oncology trial by mid‑2026, a move...
University of Michigan Shows Protein Nanoparticles Deliver Genes to Diverse Human Cells
Scientists at the University of Michigan have demonstrated that protein‑coated nanoparticles can efficiently deliver DNA and mRNA to liver cancer, kidney and immune cells in vitro, marking a potential shift away from viral vectors in gene therapy. The platform uses...
Galapagos and Gilead Ink $837.5M Framework Deal Tied to Ouro Acquisition
Galapagos NV and Gilead Sciences have signed a binding framework agreement that gives Galapagos a 50% share of the $1.675 billion upfront consideration for Gilead’s acquisition of Ouro Medicines. The deal also locks in a $500 million cash pool for Galapagos, including...
Genetic-Level Solutions Needed; Dyno Tackles Untreatable Diseases
Eric Kelsic said: "To address the root cause of a genetic disease, you need to take action at the genetic level." But this isn’t possible today. If you have sickle cell, Huntington's or cystic fibrosis, there's no cure for you just yet. Here's...
Eli Lilly Acquires Centessa for $7.8B in Neuro Push
Lilly buying $CNTA Centessa (hub & spoke R&D co) for $6.3B + $1.5B CVR. Another neuro deal. Big congrats to @Medicxi, Index ventures, General Atlantic https://t.co/jkC9dv6d3I @medicx
Can Damage to a Stressed Cell Be Reversed?
Soley Therapeutics’ co‑founder and CEO Dr. Yerem Yeghiazarians explained the company’s novel strategy of using small‑molecule drugs to reverse cellular stress rather than targeting a specific virus or gene. The platform aims to restore function in stressed cells implicated in non‑oncology...
AZ Considers Filings for Long-Acting Strensiq Follow-Up
AstraZeneca’s Alexion unit intends to file a new long‑acting enzyme replacement therapy, efzimfotase alfa, as a successor to its Strensiq (asfotase alfa) for hypophosphatasia (HPP). Phase 3 data showed the drug met primary endpoints in pediatric patients but failed to achieve...
Homoharringtonine Extends Lifespan, Fights Obesity in Mice
Researchers reported that homoharringtonine (HHT), a plant‑derived alkaloid already approved for certain blood cancers, acts as a potent senolytic in mice. The compound selectively eliminated senescent cells across adipose, liver and muscle, leading to lower inflammation, improved glucose tolerance and...
Structural and Genetic Analysis of Neutralizing Antibodies Reveals Mechanisms of GII.4 Norovirus Antigenic Evolution
Researchers solved the atomic structures of two neutralizing monoclonal antibodies against the pandemic GII.4 norovirus, targeting the principal antigenic sites A and G. The spatial positioning of site G was shown to shape neutralizing responses, while coordinated substitutions within these...
Blackstone Closes $6.3bn Life Sciences Fund
Blackstone announced the closing of its newest life sciences fund at $6.3 billion, topping the original target. The vehicle will back biotech, pharmaceutical and medical‑technology companies from seed to growth stages. Investor enthusiasm for health‑tech has surged since the pandemic, allowing...
Healing Wounded Skin without Scarring? Preclinical Research Shows Promise
Harvard researchers uncovered that post‑natal skin scarring is driven by fibroblast‑produced Cxcl12, which triggers excessive nerve growth that blocks full tissue regeneration. By deleting Cxcl12 or applying Botox to suppress local nerve signaling, mice healed wounds without scars, restoring all...
UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies
uBriGene Biosciences has entered a strategic partnership with Cellinfinity BIO to accelerate the development of in‑vivo CAR‑T therapies for both solid tumors and hematologic cancers. The collaboration will apply uBriGene’s LVV Turbo platform, which delivers up to 80% purification recovery...
UBriGene and Cellinfinity BIO Collaborate to Accelerate in Vivo CAR-T Therapies
uBriGene Biosciences has entered a strategic partnership with Cellinfinity BIO to fast‑track in‑vivo CAR‑T programs for both solid and hematologic cancers. The deal leverages uBriGene’s LVV Turbo platform, which delivers GMP‑grade lentiviral vectors with up to 80% purification recovery and...
ACC 2026: Lorundrostat Lowers BP but Raises Hyperkalemia Risk
At the 2026 ACC Scientific Session, Brazilian investigators presented a meta‑analysis of three placebo‑controlled trials (1,060 patients) evaluating lorundrostat in uncontrolled hypertension. Lorundrostat 50 mg reduced systolic blood pressure by 9.08 mm Hg and diastolic by 3.48 mm Hg, while the 100 mg dose achieved an...
Blackstone Closes Record $6.3bn Life Sciences Fund
Blackstone announced that its sixth life sciences fund, BXLS VI, closed at $6.3 billion, making it the largest private fund ever raised for the sector. The fund was oversubscribed and is about 40% larger than the $4.6 billion fifth fund closed in 2020,...
Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia
Merck presented Phase III CORALreef AddOn trial results for enlicitide decanoate, an oral PCSK9 inhibitor, in hypercholesterolemic adults on statins. At eight weeks, the drug lowered LDL‑C by 64.6%, outperforming bempedoic acid, ezetimibe and their combination. It also achieved 54.6%...
STAT+: Over-the-Top Psychedelic Promos Could Undermine the Field’s Drug Development Efforts
Psychedelic biotech firms Helus Pharma and AtaiBeckley have hired marketing agencies to produce YouTube videos that tout exaggerated efficacy claims and alleged FDA fast‑track status for their investigational drugs. The ads, labeled only as “informational,” suggest near‑perfect Phase 2 results and...
Standing Ovation Raises €30M to Scale Precision Fermentation Dairy Proteins Globally
Standing Ovation, a French precision‑fermentation startup, closed a €30 million Series B round (≈$32.5 million) led by the France 2030‑backed Ecotechnologies 2 fund and Crédit Mutuel Innovation, with participation from Danone Ventures, Bel Group and other investors. The financing includes €25 million in equity (≈$27 million) and...
Teva Advances Biosimilars Portfolio with Ponlimsi (Denosumab) FDA Approval and Dual Omalizumab Filing Acceptance
Teva Pharmaceutical received U.S. FDA approval for Ponlimsi, a biosimilar to Amgen’s Prolia (denosumab), covering all approved indications. The approval was granted after extensive analytical and clinical studies demonstrated comparable efficacy, safety, and immunogenicity to the reference product. In parallel,...
Vertically Stacked Paper‐Based Microarray Device for High‐Throughput SERS Detection of Two Cancer Biomarkers
Researchers have unveiled a vertically stacked paper‑based microarray device (µAPAD) that integrates the full immunoassay workflow for high‑throughput SERS detection of cancer biomarkers. The 16‑layer wax‑patterned platform ensures uniform nanotag distribution, cutting signal variation from 36.6% to 6.69% and enabling...
Extrahepatic Gene Editing In Vivo Using Organic Solvent‐Free Lipid Nanoparticles
Researchers have unveiled a fully water‑based lipid nanoparticle (LNP) platform that eliminates cholesterol and PEG, using poly(2‑methyl‑2‑oxazoline) as a stealth polymer. The solvent‑free formulation enables efficient delivery of CRISPR‑Cas9 components, achieving robust gene editing in primary human immune cells and...
Bioinspired Anti‐VEGF Peptide Nanoparticle with Immune Regulating and Corneal Epithelium Penetration Capability for Corneal Neovascularization Therapy
Researchers have engineered a bioinspired nanoparticle that co‑assembles an anti‑VEGF peptide with copper ions, adds a ROS‑scavenging moiety and a cell‑penetrating peptide, and achieves deep corneal delivery. The formulation extends ocular residence to roughly 70 minutes and reaches 300 µm in a...
Integrated Transcriptomics–Metabolomics Analysis Reveals Biomarkers and Metabolic Dysregulation Characteristics of Parenteral Nutrition–Associated Liver Disease
A mouse model of parenteral nutrition‑associated liver disease (PNALD) was analyzed using combined RNA‑sequencing and untargeted metabolomics. Integrated machine‑learning pipelines (LASSO and SVM‑RFE) pinpointed five gene biomarkers (Itgam, Clec4d, Orm2, Lcn2, Cd14) and three metabolites (6‑n‑octylaminouracil, 6β‑hydroxy‑hydromorphone, α‑teresantalic acid). These...
Tirzepatide Cuts Cardiorenal Events 14% vs Dulaglutide in Landmark Trial
A post‑hoc analysis of the SURPASS‑CVOT trial finds the dual GLP‑1/GIP agonist tirzepatide lowers a broad six‑component cardiorenal endpoint by 14% compared with the GLP‑1‑only drug dulaglutide. The result, presented at ACC 2026, could reshape how biohackers approach metabolic health...
Aurinia to Acquire Kezar for $6.96 per Share, Adding Immunoproteasome Asset
Aurinia Pharmaceuticals announced a definitive agreement to acquire Kezar Life Sciences for $6.955 in cash per share plus a contingent value right (CVR). The deal, slated to close in Q2 2026, gives Aurinia access to Kezar’s lead immunoproteasome inhibitor, zetomipzomib, and...
Right Through the Skull
Researchers have unveiled a novel calvarial delivery platform that injects drug‑laden nanoparticles into the skull’s bone marrow. Immune cells within the diploic space capture the particles and migrate across skull‑meninges channels, ferrying the therapeutic cargo into the brain. In mouse...
Common Ancestry Limits Protein Sequence Exploration, Computational Study Shows
Researchers from OIST, ISTA, Vienna and CAB published a computational study in PNAS showing that common ancestry, rather than selection or epistasis, is the primary constraint on protein sequence diversification. By estimating the effective dimensionality of protein families and simulating...
GDF15: AI‑derived Senescence Marker Predicts Mortality
Hopefully blood testing companies can measure GDF15 sooner than later... A deep-learning based biomarker of systemic cellular senescence burden to predict mortality and health outcomes https://t.co/lqM7w3aPfJ
Immune Modulation Preps FDA Submission for Parkinson's Drug After 30‑Year Journey
Immune Modulation, Inc. announced it is finalizing pre‑IND toxicology and pharmacokinetic studies to file an FDA submission for hypoestoxide, a plant‑derived anti‑inflammatory candidate for Parkinson's disease. The move caps a 30‑year scientific trek that began with a rainforest compound identified...
United Therapeutics Shares Surge 12% on Positive TETON-1 Phase III Results
United Therapeutics reported that its TETON-1 Phase III trial met the primary endpoint, delivering a 130.1 mL improvement in forced vital capacity for idiopathic pulmonary fibrosis patients. The news lifted the stock more than 12% and set the company on a path...
Neurolief Secures $6 Million Investment After FDA Clears First At‑Home Brain Neuromodulation Therapy
Neurolief announced a $6 million milestone‑based investment from BrainsWay Ltd. following the FDA’s Premarket Approval of its Proliv™Rx at‑home brain neuromodulation system. The clearance marks the first prescription‑grade, home‑use device for adults whose depression has not responded to at least one...
Tevogen Bio Holdings Inc (TVGN) Q4 2025 Earnings Call Transcript
VistaGen Therapeutics reported completing the randomized portion of its PALISADE III Phase 3 trial and using the data to implement operational and statistical refinements for the ongoing PALISADE IV study. The company is leveraging third‑party AI and machine learning to...
Kairos Pharma Ltd (KAPA) Q4 2025 Earnings Call Transcript
Karyopharm Therapeutics posted Q4 2025 revenue of $34.1 million, an 11.8% year‑over‑year increase, while total 2025 revenue reached $146.1 million. Operating efficiency improved, with R&D and SG&A expenses down 17% and 16% respectively, yet the company recorded a GAAP net loss of...
Bioatla Inc (BCAB) Q4 2025 Earnings Call Transcript
BioAtla reported that it is in the final stages of a strategic partnership transaction expected to close by year‑end and disclosed FDA alignment on the phase‑3 design of its OSFI (OSV) trial for second‑line oropharyngeal squamous cell carcinoma. The trial...
Galmed Pharmaceuticals Ltd (GLMD) Q4 2025 Earnings Call Transcript
MediWound reported a sharp Q4 revenue drop to $1.9 million, driven primarily by a U.S. government shutdown that delayed contract awards. R&D spending rose to $4.5 million as the company pushed the Phase III VALUE study for its EscharEx wound‑debridement therapy. A new...